ClinicalTrials.Veeva

Find clinical trials for Multiple Myeloma in Chicago, IL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Leukemia
Cancer
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Chicago, IL, USA:

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

dexamethasone is effective and safe when given to people who have multiple myeloma that has gotten worse and is not responding to s ...

Enrolling
Relapse Multiple Myeloma
Multiple Myeloma
Drug: Dexamethasone
Drug: Carfilzomib

Phase 2

The University of Chicago
The University of Chicago

Chicago, Illinois, United States

a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple...

Active, not recruiting
Multiple Myeloma in Relapse
Multiple Myeloma
Drug: Lenalidomide
Drug: Dexamethasone

Phase 1

Alliance Foundation Trials (AFT)

Maywood, Illinois, United States and 4 other locations

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

Phase 3

Janssen
Janssen

Chicago, Illinois, United States and 145 other locations

(BCMA)-specific chimeric antigen receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated as a single agent in multiple...

Active, not recruiting
Multiple Myeloma
Biological: PHE885

Phase 1

Novartis
Novartis

Chicago, Illinois, United States and 12 other locations

This study will be a multi-center, open-label, Phase 2 study where newly diagnosed Multiple Myeloma requiring systemic chemotherapy...

Active, not recruiting
Multiple Myeloma
Drug: Elotuzumab
Drug: Lenalidomide

Phase 2

The University of Chicago
The University of Chicago

Chicago, Illinois, United States and 2 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Enrolling
Multiple Myeloma
Drug: Carfilzomib
Drug: CC-92480

Phase 1, Phase 2

Celgene
Celgene

Chicago, Illinois, United States and 49 other locations

This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and pre...

Enrolling
Multiple Myeloma
Drug: NMS-03597812
Drug: NMS-03597812 + dexamethasone

Phase 1

Nerviano Medical Sciences

Chicago, Illinois, United States and 5 other locations

of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...

Active, not recruiting
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

Phase 2

AbbVie
AbbVie

Chicago, Illinois, United States and 39 other locations

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in...

Enrolling
Multiple Myeloma
Drug: Venetoclax
Drug: Dexamethasone

Phase 2

AbbVie
AbbVie

Chicago, Illinois, United States and 31 other locations

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Carfilzomib

Phase 3

Celgene
Celgene

Chicago, Illinois, United States and 59 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems